Results 41 to 50 of about 72,428 (200)

Patient‐Reported Outcomes with Selpercatinib Treatment Among Patients with RET‐Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO‐001 Trial

The Oncologist, EarlyView., 2021
Abstract Background Medullary thyroid cancer (MTC) standard of care includes multikinase inhibitors (MKIs), which can exacerbate disease‐related diarrhea, primarily because of non‐RET kinase inhibition. We report diarrhea and other patient‐reported outcomes (PROs) with selpercatinib, a highly selective RET inhibitor, among patients with RET‐mutant MTC ...
Lori J. Wirth, Bruce Robinson, Valentina Boni, Daniel S.W. Tan, Caroline McCoach, Erminia Massarelli, Lisa M. Hess, Min‐Hua Jen, Jennifer Kherani, Elizabeth Olek, Vivek Subbiah   +10 more
wiley   +1 more source

Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis

BMC Cancer, 2018
Background Sorafenib and transarterial chemoembolization (TACE) might both provide survival benefit for advanced hepatocellular carcinoma (HCC). Adopting either as a first-line therapy carries major cost and resource implications.
Shuling Chen, Zhenwei Peng, Mengchao Wei, Weifeng Liu, Zihao Dai, Haibo Wang, Jie Mei, Mingfong Cheong, Hanmei Zhang, Ming Kuang   +9 more
doaj   +1 more source

TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma

Frontiers in Pharmacology, 2020
PurposeTo investigate the effectiveness and safety of transarterial chemoembolization (TACE) combined with sorafenib and thermal ablation in patients with huge hepatocellular carcinoma (HCC).Materials and MethodsThis retrospective study examined 50 ...
Ying Wu, Ying Wu, Han Qi, Han Qi, Fei Cao, Fei Cao, Lujun Shen, Lujun Shen, Shuanggang Chen, Shuanggang Chen, Lin Xie, Lin Xie, Tao Huang, Tao Huang, Ze Song, Danyang Zhou, Danyang Zhou, Weijun Fan, Weijun Fan   +18 more
doaj   +1 more source

Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma

Cell Communication and Signaling, 2023
Background Sorafenib improves the overall survival in patients with advanced hepatocellular carcinoma (HCC). Dickkopf-1 (DKK1) is commonly overexpressed in HCC.
Sang Hyun Seo, Kyung Joo Cho, Hye Jung Park, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Jae Hee Cheon, Jong In Yook, Man-Deuk Kim, Dong Jin Joo, Seung Up Kim   +12 more
doaj   +1 more source

Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells

Cancer Biology & Medicine, 2022
Objective: Sorafenib is a first-line drug for advanced hepatocellular carcinoma (HCC). Unfortunately, most patients with HCC do not respond to sorafenib, mainly because of the frequent development of drug resistance.
Leyi Yao, Qian Zhao, Ding Yan, Ziying Lei, Yali Hao, Jinghong Chen, Qian Xue, Xiaofen Li, Qingtian Huang, Daolin Tang, Q. Ping Dou, Xin Chen, Jinbao Liu   +12 more
doaj   +1 more source

UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma

Signal Transduction and Targeted Therapy, 2021
The treatment for hepatocellular carcinoma (HCC) is promising in recent years, but still facing critical challenges. The first targeted therapy, sorafenib, prolonged the overall survival by months.
Junjie Xu, Lin Ji, Yeling Ruan, Zhe Wan, Zhongjie Lin, Shunjie Xia, Liye Tao, Junhao Zheng, Liuxin Cai, Yifan Wang, Xiao Liang, Xiujun Cai   +11 more
doaj   +1 more source

ABHD12 contributes to tumorigenesis and sorafenib resistance by preventing ferroptosis in hepatocellular carcinoma

iScience, 2023
Summary: Sorafenib induces ferroptosis, making it a useful treatment against advanced liver hepatocellular carcinoma (LIHC). However, sorafenib resistance is extremely common among LIHC patients.
Mengxing Cai, Jingwen Luo, Chunxiu Yang, Xiaopeng Yang, Cheng Zhang, Lixin Ma, Yibin Cheng   +6 more
doaj   +1 more source

RNA m6A methylation regulates sorafenib resistance in liver cancer through FOXO3‐mediated autophagy

EMBO Journal, 2020
N6‐methyladenosine (m6A) is an abundant nucleotide modification in mRNA, known to regulate mRNA stability, splicing, and translation, but it is unclear whether it is also has a physiological role in the intratumoral microenvironment and cancer drug ...
Ziyou Lin, Y. Niu, Arabella H Wan, Dongshi Chen, Heng-xing Liang, Xijun Chen, Lei Sun, Siyue Zhan, Liutao Chen, Chao Cheng, Xiaolei Zhang, Xianzhang Bu, Wei-ling He, Guohui Wan   +13 more
semanticscholar   +1 more source

Effects of Sorafenib and Quercetin Alone or in Combination in Treating Hepatocellular Carcinoma: In Vitro and In Vivo Approaches

Molecules, 2022
Sorafenib is the first drug approved to treat advanced hepatocellular carcinoma (HCC) and continues as the gold-standard therapy against HCC. However, acquired drug resistance represents a main concern about sorafenib therapy.
Suzan B. S. Abdu, Nouf Juaid, A. Amin, M. Moulay, N. Miled   +4 more
semanticscholar   +1 more source

ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma

Neoplasia: An International Journal for Oncology Research, 2021
Sorafenib is a first-line molecular-target drug for advanced hepatocellular carcinoma (HCC), and reducing sorafenib resistance is an important issue to be resolved for the clinical treatment of HCC.
Wenbin Huang, Kunling Chen, Yishi Lu, Donghui Zhang, Yuan Cheng, Liuran Li, Weimei Huang, Guolin He, Hangyu Liao, Lei Cai, Yujun Tang, Liang Zhao, Mingxin Pan   +12 more
doaj   +1 more source